The three M's: Melanoma, microphthalmia-associated transcription factor and microRNA

Pigment Cell and Melanoma Research

Volumn 24, Issue 6, 2011, Pages 1088-1106

  Bell, Rachel E ^a   Levy, Carmit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer models; Melanoma; MicroRNA; MITF

Indexed keywords

MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA;

CANCER GROWTH; CANCER MODEL; CANCER STEM CELL; CANCER THERAPY; CELL FUNCTION; GENETIC ANALYSIS; HUMAN; MELANOCYTE; MELANOMA; NEOPLASM; NONHUMAN; PHENOTYPE; PIGMENT CELL; PROTEIN EXPRESSION; REVIEW; STOCHASTIC MODEL;

ANIMALS; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; SKIN NEOPLASMS;

EID: 82055185041     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00931.x     Document Type: Review

References (258)

1. Adams, J.M., and Strasser, A. (2008). Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 68, 4018-4021.
2. Adams, B.D., Claffey, K.P., and White, B.A. (2009). Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology 150, 14-23.
3. Aguirre-Ghiso, J.A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846.
4. Albertson, D.G., Collins, C., Mccormick, F., and Gray, J.W. (2003). Chromosome aberrations in solid tumors. Nat. Genet. 34, 369-376.
5. Alexaki, V.-I., Javelaud, D., Van Kempen, L.C.L. et al. (2010). GLI2-mediated melanoma invasion and metastasis. J. Natl Cancer Inst. 102, 1148-1159.
6. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988.
7. Alon, U. (2007). Network motifs: theory and experimental approaches. Nature reviews. Genetics 8, 450-461.
8. Alonso, S.R., Tracey, L., Ortiz, P. et al. (2007). A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 67, 3450-3460.
9. Alvarez-Garcia, I., and Miska, E.A. (2005). MicroRNA functions in animal development and human disease. Development 132, 4653-4662.
10. Amiel, J., Watkin, P.M., Tassabehji, M., Read, A.P., and Winter, R.M. (1998). Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome). Clin. Dysmorphol 7, 17-20.
11. Aoki, H., and Moro, O. (2002). Involvement of microphthalmia-associated transcription factor (MITF) in expression of human melanocortin-1 receptor (MC1R). Life Sci. 71, 2171-2179.
12. Argani, P., Lui, M.Y., Couturier, J., Bouvier, R., Fournet, J.-C., and Ladanyi, M. (2003). A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 22, 5374-5378.
13. Arozarena, I., Bischof, H., Gilby, D., Belloni, B., Dummer, R., and Wellbrock, C. (2011). In melanoma, beta-catenin is a suppressor of invasion. Oncogene doi:.
14. Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
15. Bartel, D.P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
16. Baxter, L.L., Loftus, S.K., and Pavan, W.J. (2009). Networks and pathways in pigmentation, health, and disease. Wiley Interdiscip. Rev. Syst. Biol. Med. 1, 359-371.
17. Bemis, L.T., Chen, R., Amato, C.M., Classen, E.H., Robinson, S.E., Coffey, D.G., Erickson, P.F., Shellman, Y.G., and Robinson, W.A. (2008). MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 68, 1362-1368.
18. Berger, M.F., Levin, J.Z., Vijayendran, K. et al. (2010). Integrative analysis of the melanoma transcriptome. Genome Res. 20, 413-427.
19. Beuret, L., Ohanna, M., Strub, T., Allegra, M., Davidson, I., Bertolotto, C., and Ballotti, R. (2011). BRCA1 is a new MITF target gene. Pigment Cell Melanoma Res. 24, 725-727.
20. Bishop, D.T., Demenais, F., Iles, M.M. et al. (2009). Genome-wide association study identifies three loci associated with melanoma risk. Nat. Genet. 41, 920-925.
21. Bissell, M.J., and Hines, W.C. (2011). Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17, 320-329.
22. Boeckmann, B., Blatter, M.-C., Famiglietti, L., Hinz, U., Lane, L., Roechert, B., and Bairoch, A. (2005). Protein variety and functional diversity: Swiss-Prot annotation in its biological context. C. R. Biol. 328, 882-899.
23. Boeri, M., Verri, C., Conte, D., Roz, L., Modena, P., Facchinetti, F., Calabrò, E., Croce, C.M., Pastorino, U., and Sozzi, G. (2011). MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. USA 108, 3713-3718.
24. Bollag, G., Hirth, P., Tsai, J. et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
25. Bonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.
26. Botton, T., Puissant, A., Cheli, Y. et al. (2011). Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. Cell Death Differ. 18, 109-121.
27. Boyle, G.M., Pedley, J., Martyn, A.C., Banducci, K.J., Strutton, G.M., Brown, D.A., Breit, S.N., and Parsons, P.G. (2008). Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J. Invest. Dermatol. 129, 383-391.
28. Boyle, G.M., Woods, S.L., Bonazzi, V.F., Stark, M.S., Hacker, E., Aoude, L.G., Dutton-Regester, K., Cook, A.L., Sturm, R.A., and Hayward, N.K. (2011). Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 24, 525-537.
29. Buscà, R., Berra, E., Gaggioli, C. et al. (2005). Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J. Cell Biol. 170, 49-59.
30. Calin, G.A., and Croce, C.M. (2006). MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866.
31. Calin, G.A., Sevignani, C., Dumitru, C.D. et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 101, 2999-3004.
32. Caramuta, S., Egyhazi, S., Rodolfo, M., Witten, D., Hansson, J., Larsson, C., and Lui, W.-O. (2010). MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol. 130, 2062-2070.
33. Carreira, S., Liu, B., and Goding, C.R. (2000). The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J. Biol. Chem. 275, 21920-21927.
34. Carreira, S., Goodall, J., Aksan, I., La Rocca, S.A., Galibert, M.-D., Denat, L., Larue, L., and Goding, C.R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433, 764-769.
35. Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 3426-3439.
36. Chan, E., Patel, R., Nallur, S. et al. (2011). MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 10, 1845-1852.
37. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
38. Cheli, Y., Ohanna, M., Ballotti, R., and Bertolotto, C. (2010). Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 23, 27-40.
39. Cheli, Y., Giuliano, S., Fenouille, N. et al. (2011a). Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene doi:.
40. Cheli, Y., Guiliano, S., Botton, T., Rocchi, S., Hofman, V., Hofman, P., Bahadoran, P., Bertolotto, C., and Ballotti, R. (2011b). Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30, 2307-2318.
41. Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., and Guo, X. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997-1006.
42. Chen, J., Feilotter, H.E., Pare, G.C., Zhang, X., Pemberton, J.G., Garady, C., Lai, D., Yang, X., and Tron, V.A. (2010). MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 176, 2520-2529.
43. Cho, W.C. (2007). OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 6, 60.
44. Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H.M., Jones, D.L., Visvader, J., Weissman, I.L., and Wahl, G.M. (2006). Cancer stem cells-perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 66, 9339-9344.
45. Collins, A.T., Berry, P.A., Hyde, C., Stower, M.J., and Maitland, N.J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951.
46. Croce, C.M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Gen. 10, 704-714.
47. Cronin, J.C., Wunderlich, J., Loftus, S.K. et al. (2009). Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res. 22, 435-444.
48. Cui, Q., Yu, Z., Purisima, E.O., and Wang, E. (2006). Principles of microRNA regulation of a human cellular signaling network. Mol. Syst. Biol. 2, 46.
49. Dalerba, P., Cho, R.W., and Clarke, M.F. (2007a). Cancer stem cells: models and concepts. Annu. Rev. Med. 58, 267-284.
50. Dalerba, P., Dylla, S.J., Park, I.-K. et al. (2007b). Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 104, 10158-10163.
51. Dick, J.E. (2003). Breast cancer stem cells revealed. Proc. Natl. Acad. Sci. USA 100, 3547-3549.
52. Du, J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., Ross, K., Huber, W.E., Nishimura, E.K., Golub, T.R., and Fisher, D.E. (2004). Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565-576.
53. Dynek, J.N., Chan, S.M., Liu, J., Zha, J., Fairbrother, W.J., and Vucic, D. (2008). Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 68, 3124-3132.
54. Eichhoff, O.M., Weeraratna, A., Zipser, M.C. et al. (2011). Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res. 24, 631-642.
55. Esquela-Kerscher, A., and Slack, F.J. (2006). Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269.
56. Esquela-Kerscher, A., Trang, P., Wiggins, J.F., Patrawala, L., Cheng, A., Ford, L., Weidhaas, J.B., Brown, D., Bader, A.G., and Slack, F.J. (2008). The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7, 759-764.
57. Esteller, M. (2007a). Cancer epigenomics: DNA methylomes and histone-modification maps. Nature reviews. Genetics 8, 286-298.
58. Esteller, M. (2007b). Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 16, R50-R59.
59. Esteller, M. (2008). Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159.
60. Fidler, I.J. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458.
61. Francken, A., Accortt, N., Shaw, H., Wiener, M., Soong, S.-J., Hoekstra, H., and Thompson, J. (2008). Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann. Surg. Oncol. 15, 1476-1484.
62. Friedman, A., and Perrimon, N. (2007). Genetic screening for signal transduction in the era of network biology. Cell 128, 225-231.
63. Friedman, R.C., Farh, K.K.-H., Burge, C.B., and Bartel, D.P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92-105.
64. Garbe, C., Eigentler, T.K., Keilholz, U., Hauschild, A., and Kirkwood, J.M. (2011). Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5-24.
65. Garofalo, M., and Croce, C.M. (2011). microRNAs: master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 51, 25-43.
66. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
67. Gaur, A., Jewell, D.A., Liang, Y., Ridzon, D., Moore, J.H., Chen, C., Ambros, V.R., and Israel, M.A. (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 67, 2456-2468.
68. Ghosh, P., and Chin, L. (2009). Genetics and genomics of melanoma. Expert Rev. Dermatol. 4, 131.
69. Giampieri, S., Manning, C., Hooper, S., Jones, L., Hill, C.S., and Sahai, E. (2009). Localized and reversible TGF[beta] signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 11, 1287-1296.
70. Gilad, S., Meiri, E., Yogev, Y. et al. (2008). Serum microRNAs are promising novel biomarkers. PLoS ONE 3, e3148.
71. Giuliano, S., Cheli, Y., Ohanna, M. et al. (2010). Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res. 70, 3813-3822.
72. Glud, M., Klausen, M., Gniadecki, R., Rossing, M., Hastrup, N., Nielsen, F.C., and Drzewiecki, K.T. (2008). MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J. Invest. Dermatol. 129, 1219-1224.
73. Glud, M., Manfe, V., Biskup, E., Holst, L., Dirksen, A.M., Hastrup, N., Nielsen, F.C., Drzewiecki, K.T., and Gniadecki, R. (2011). MicroRNA miR-125b induces senescence in human melanoma cells. Melanoma Res. 21, 253-256.
74. Goding, C.R. (2011). A picture of Mitf in melanoma immortality. Oncogene 30, 2304-2306.
75. Goswami, S., Tarapore, R.S., Teslaa, J.J., Grinblat, Y., Setaluri, V., and Spiegelman, V.S. (2010). MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor mRNA is inhibited by the coding region determinant-binding protein. J. Biol. Chem. 285, 20532-20540.
76. Greaves, M. (2010). Cancer stem cells: back to Darwin? Semin. Cancer Biol. 20, 65-70.
77. Greenberg, E., Hershkovitz, L., Itzhaki, O. et al. (2011). Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS ONE 6, e18936.
78. Grignol, V., Fairchild, E.T., Zimmerer, J.M. et al. (2011). miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. Br. J. Cancer 105, 1023-1029.
79. Grosshans, H., and Chatterjee, S. (2010). MicroRNAses and the regulated degradation of mature animal miRNAs. Adv. Exp. Med. Biol. 700, 140-155.
80. Gupta, P.B., Chaffer, C.L., and Weinberg, R.A. (2009). Cancer stem cells: mirage or reality? Nat. Med. 15, 1010-1012.
81. Gupta, P.B., Fillmore, C.M., Jiang, G., Shapira, S.D., Tao, K., Kuperwasser, C., and Lander, E.S. (2011). Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644.
82. Haflidadottir, B.S., Bergsteinsdottir, K., Praetorius, C., and Steingri-Msson, E. (2010). miR-148 regulates Mitf in melanoma cells. PLoS ONE 5, e11574.
83. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
84. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
85. Hansford, L.M., Mckee, A.E., Zhang, L. et al. (2007). Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res. 67, 11234-11243.
86. Haq, R., and Fisher, D.E. (2011). Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J. Clin. Oncol. 29, 3474-3482.
87. Held, M.A., Curley, D.P., Dankort, D., Mcmahon, M., Muthusamy, V., and Bosenberg, M.W. (2010). Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res. 70, 388-397.
88. Hemesath, T.J., Steingrímsson, E., McGill, G., Hansen, M.J., Vaught, J., Hodgkinson, C.A., Arnheiter, H., Copeland, N.G., and Fisher, D.E. (1994). Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 8, 2770-2780.
89. Hirobe, T. (2011). How are proliferation and differentiation of melanocytes regulated? Pigment Cell Melanoma Res. 24, 462-478.
90. HMDD (2011). Human MiRNA & Disease Database (HMDD).
91. Hoek, K.S., and Goding, C.R. (2010). Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 23, 746-759.
92. Hoek, K.S., Schlegel, N.C., Sucker, A. et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19, 290-302.
93. Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., and Dummer, R. (2008a). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650-656.
94. Hoek, K.S., Schlegel, N.C., Eichhoff, O.M. et al. (2008b). Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res. 21, 665-676.
95. Horner, M.J., Ries, L.A.G., Krapcho, M. et al. (2009). SEER Cancer Statistics Review, 1975-2006. (Bethesda, MD: National Cancer Institute)., based on November 2008 SEER data submission, posted to the SEER web site, 2009.
96. Hornstein, E., and Shomron, N. (2006). Canalization of development by microRNAs. Nat. Genet. 38 (Suppl), S20-24.
97. Hornyak, T.J., Jiang, S., Guzmán, E.A., Scissors, B.N., Tuchinda, C., He, H., Neville, J.D., and Strickland, F.M. (2009). Mitf dosage as a primary determinant of melanocyte survival after ultraviolet irradiation. Pigment Cell Melanoma Res. 22, 307-318.
98. Hou, L., and Pavan, W.J. (2008). Transcriptional and signaling regulation in neural crest stem cell-derived melanocyte development: do all roads lead to Mitf? Cell Res. 18, 1163-1176.
99. Howlader, N., Noone, A.M., Krapcho, M. et al. (2011). SEER Cancer Statistics Review, 1975-2008. (Bethesda, MD: National Cancer Institute), based on November 2010 SEER data submission, posted to the SEER web site, 2011.
100. Hugo, H., Ackland, M.L., Blick, T., Lawrence, M.G., Clements, J.A., Williams, E.D., and Thompson, E.W. (2007). Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 213, 374-383.
101. Hurst, D.R., Edmonds, M.D., and Welch, D.R. (2009). Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 69, 7495-7498.
102. Jaeger, J., Koczan, D., Thiesen, H.-J., Ibrahim, S.M., Gross, G., Spang, R., and Kunz, M. (2007). Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin. Cancer Res. 13, 806-815.
103. Javelaud, D., Alexaki, V.I., Pierrat, M.J. et al. (2011). GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Pigment Cell Melanoma Res. 24, 932-943.
104. Jeffs, A.R., Glover, A.C., Slobbe, L.J. et al. (2009). A gene expression signature of invasive potential in metastatic melanoma cells. PLoS ONE 4, e8461.
105. Jiang, J., Lee, E.J., Gusev, Y., and Schmittgen, T.D. (2005). Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 33, 5394-5403.
106. Joo, K.M., Kim, S.Y., Jin, X. et al. (2008). Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Invest. 88, 808-815.
107. Joyce, J.A., and Pollard, J.W. (2009). Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252.
108. Jukic, D., Rao, U., Kelly, L., Skaf, J., Drogowski, L., Kirkwood, J., and Panelli, M. (2010). MicroRNA profiling analysis of differences between the melanoma of young adults and older adults. J. Transl. Med. 1, 1-23.
109. Kanemaru, H., Fukushima, S., Yamashita, J. et al. (2011). The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 61, 187-193.
110. Karube, Y., Tanaka, H., Osada, H. et al. (2005). Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 96, 111-115.
111. Kelly, P.N., Dakic, A., Adams, J.M., Nutt, S.L., and Strasser, A. (2007). Tumor growth need not be driven by rare cancer stem cells. Science 317, 337.
112. Khaitan, D., Sankpal, U., Weksler, B., Meister, E., Romero, I., Couraud, P.-O., and Ningaraj, N. (2009). Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer 9, 258.
113. Khaled, M., Levy, C., and Fisher, D.E. (2010). Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev. 24, 2276-2281.
114. Khan, J., Wei, J.S., Ringnér, M. et al. (2001). Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 7, 673.
115. Kholmanskikh, O., Van Baren, N., Brasseur, F., Ottaviani, S., Vanacker, J., Arts, N., Van Der Bruggen, P., Coulie, P., and De Plaen, E. (2010). Interleukins 1α and 1β secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. Int. J. Cancer 127, 1625-1636.
116. Kido, K., Sumimoto, H., Asada, S., Okada, S.M., Yaguchi, T., Kawamura, N., Miyagishi, M., Saida, T., and Kawakami, Y. (2009). Simultaneous suppression of MITF and BRAFV600E enhanced inhibition of melanoma cell proliferation. Cancer Sci. 100, 1863-1869.
117. Kim, V.N. (2005). MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6, 376-385.
118. King, R., Weilbaecher, K.N., McGill, G.L., Cooley, E., Mihm, M., and Fisher, D.E. (1999). Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am. J. Pathol. 155, 731-738.
119. Klymkowsky, M.W., and Savagner, P. (2009). Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am. J. Pathol. 174, 1588-1593.
120. Kobi, D., Steunou, A.L., Dembele, D., Legras, S., Larue, L., Nieto, L., and Davidson, I. (2010). Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene. Pigment Cell Melanoma Res. 23, 404-418.
121. Koga, Y., Pelizzola, M., Cheng, E., Krauthammer, M., Sznol, M., Ariyan, S., Narayan, D., Molinaro, A.M., Halaban, R., and Weissman, S.M. (2009). Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res. 19, 1462-1470.
122. Kota, J., Chivukula, R.R., O'Donnell, K.A. et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017.
123. Kreeger, P.K., and Lauffenburger, D.A. (2010). Cancer systems biology: a network modeling perspective. Carcinogenesis 31, 2-8.
124. Kubick, B.J., and Roop, D.R. (2011). A fitness model for melanoma-initiating cells. Pigment Cell Melanoma Res. 24, 396-397.
125. Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R., and Jacks, T. (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39, 673-677.
126. Lee, E.J., Baek, M., Gusev, Y., Brackett, D.J., Nuovo, G.J., and Schmittgen, T.D. (2008). Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA 14, 35-42.
127. Leidinger, P., Keller, A., Borries, A., Reichrath, J., Rass, K., Jager, S., Lenhof, H.-P., and Meese, E. (2010). High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 10, 262.
128. Levati, L., Alvino, E., Pagani, E. et al. (2009). Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int. J. Oncol. 35, 393-400.
129. Levy, C., and Fisher, D.E. (2011). Dual roles of lineage restricted transcription factors: the case of MITF in melanocytes. Transcription 2, 19-22.
130. Levy, C., Khaled, M., and Fisher, D.E. (2006). MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406-414.
131. Levy, C., Khaled, M., Iliopoulos, D. et al. (2010a). Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol. Cell 40, 841-849.
132. Levy, C., Khaled, M., Robinson, K.C. et al. (2010b). Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 141, 994-1005.
133. Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., Wicha, M., Clarke, M.F., and Simeone, D.M. (2007). Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037.
134. Liew, D.N., Kano, H., Kondziolka, D., Mathieu, D., Niranjan, A., Flickinger, J.C., Kirkwood, J.M., Tarhini, A., Moschos, S., and Lunsford, L.D. (2011). Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J. Neurosurg. 114, 769-779.
135. Lin, J.Y., and Fisher, D.E. (2007). Melanocyte biology and skin pigmentation. Nature 445, 843-850.
136. Lin, W.M., Baker, A.C., Beroukhim, R. et al. (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68, 664-673.
137. Liu, F., Fu, Y., and Meyskens Jr, F.L. (2008). MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J. Invest. Dermatol. 129, 422-431.
138. Liu, A., Tetzlaff, M.T., Vanbelle, P., Elder, D., Feldman, M., Tobias, J.W., Sepulveda, A.R., and Xu, X. (2009). MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int. J. Clin. Exp. Pathol. 2, 519-527.
139. Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Korner, H., Knyazev, P., Diebold, J., and Hermeking, H. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. In Cell Cycle 7, 2591-2600.
140. Loercher, A.E., Tank, E.M.H., Delston, R.B., and Harbour, J.W. (2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168, 35-40.
141. Lowings, P., Yavuzer, U., and Goding, C.R. (1992). Positive and negative elements regulate a melanocyte-specific promoter. Mol. Cell. Biol. 12, 3653-3662.
142. Lu, J., Getz, G., Miska, E.A. et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
143. Lu, M., Zhang, Q., Deng, M., Miao, J., Guo, Y., Gao, W., and Cui, Q. (2008). An analysis of human microRNA and disease associations. PLoS ONE 3, e3420.
144. Lujambio, A., Calin, G.A., Villanueva, A. et al. (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA 105, 13556-13561.
145. Ma, L., and Weinberg, R.A. (2008). Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet. 24, 448-456.
146. Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E.G., Teruya-Feldstein, J., Bell, G.W., and Weinberg, R.A. (2010a). Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341-347.
147. Ma, L., Young, J., Prabhala, H. et al. (2010b). miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12, 247-256.
148. Ma, Z., Swede, H., Cassarino, D., Fleming, E., Fire, A., and Dadras, S.S. (2011). Up-regulated dicer expression in patients with cutaneous melanoma. PLoS ONE 6, e20494.
149. MacKie, R.M., Reid, R., and Junor, B. (2003). Fatal melanoma transferred in a donated kidney 16years after melanoma surgery. N. Engl. J. Med. 348, 567-568.
150. Madsen, C.D., and Sahai, E. (2010). Cancer dissemination-lessons from leukocytes. Dev. Cell 19, 13-26.
151. Maenhaut, C., Dumont, J.E., Roger, P.P., and Van Staveren, W.C.G. (2010). Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis 31, 149-158.
152. Mani, S.A., Guo, W., Liao, M.-J. et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
153. Mazar, J., Deyoung, K., Khaitan, D., Meister, E., Almodovar, A., Goydos, J., Ray, A., and Perera, R.J. (2010). The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS ONE 5, e13779.
154. McAllister, S.S., and Weinberg, R.A. (2010). Tumor-host interactions: a far-reaching relationship. J. Clin. Oncol. 28, 4022-4028.
155. McGill, G.G., Horstmann, M., Widlund, H.R. et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718.
156. McGill, G.G., Haq, R., Nishimura, E.K., and Fisher, D.E. (2006). c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem. 281, 10365-10373.
157. Medic, S., Rizos, H., and Ziman, M. (2011). Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochem. Biophys. Res. Commun. 411, 832-837.
158. Melnikova, V.O., and Bar-Eli, M. (2009). Inflammation and melanoma metastasis. Pigment Cell Melanoma Res. 22, 257-267.
159. Melo, S.A., and Esteller, M. (2011). A precursor microRNA in a cancer cell nucleus: get me out of here! Cell Cycle 10, 922-925.
160. Melo, S.A., Ropero, S., Moutinho, C. et al. (2009). A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat. Genet. 41, 365-370.
161. Melo, S.A., Moutinho, C., Ropero, S. et al. (2010). A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18, 303-315.
162. Merrill, R.M. (2011). Risk-adjusted melanoma skin cancer incidence rates in Whites (United States). Melanoma Res. doi:.
163. Merritt, W.M., Lin, Y.G., Han, L.Y. et al. (2008). Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 2641-2650.
164. Molnár, V., Tamási, V., Bakos, B., Wiener, Z., and Falus, A. (2008). Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin. Cancer Biol. 18, 111-122.
165. Motyckova, G., Weilbaecher, K.N., Horstmann, M., Rieman, D.J., Fisher, D.Z., and Fisher, D.E. (2001). Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc. Natl Acad. Sci. USA 98, 5798-5803.
166. Mueller, D.W., and Bosserhoff, A.-K. (2010). The evolving concept of 'melano-miRs'- microRNAs in melanomagenesis. Pigment Cell Melanoma Res. 23, 620-626.
167. Mueller, D.W., Rehli, M., and Bosserhoff, A.K. (2009). miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol. 129, 1740-1751.
168. Munker, R., and Calin, G.A. (2011). MicroRNA profiling in cancer. Clin. Sci. (Lond.) 121, 141-158.
169. Murphy, M.J., and Carlson, J.A. (2011). Melanocytic Neoplasms II: Molecular Staging Molecular Diagnostics in Dermatology and Dermatopathology, M.J. Murphy, ed. (New York: Humana Press), pp. 105-130.
170. Nguyen, D.X., Bos, P.D., and Massague, J. (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9, 274-284.
171. Nicoloso, M.S., Spizzo, R., Shimizu, M., Rossi, S., and Calin, G.A. (2009). MicroRNAs - the micro steering wheel of tumour metastases. Nat. Rev. Cancer 9, 293-302.
172. Nishimura, E.K., Granter, S.R., and Fisher, D.E. (2005). Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 307, 720-724.
173. Nowell, P.C. (1976). The clonal evolution of tumor cell populations. Science 194, 23-28.
174. Oh, Y.-K., and Park, T.G. (2009). siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 61, 850-862.
175. Ossowski, L., and Aguirre-Ghiso, J.A. (2010). Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. 23, 41-56.
176. Ozsolak, F., Song, J.S., Liu, X.S., and Fisher, D.E. (2007). High-throughput mapping of the chromatin structure of human promoters. Nat. Biotechnol. 25, 244-248.
177. Palmieri, G., Capone, M., Ascierto, M.L., Gentilcore, G., Stroncek, D.F., Casula, M., Sini, M.C., Palla, M., Mozzillo, N., and Ascierto, P.A. (2009). Main roads to melanoma. J. Transl. Med. 7, 86.
178. Peer, D., and Lieberman, J. (2011). Special delivery: targeted therapy with small RNAs. Gene Ther. doi:.
179. Pepper, J.W., Scott Findlay, C., Kassen, R., Spencer, S.L., and Maley, C.C. (2009). SYNTHESIS: cancer research meets evolutionary biology. Evol. Appl. 2, 62-70.
180. Peter, M.E. (2009). Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8, 843-852.
181. Petricka, J.J., and Benfey, P.N. (2011). Reconstructing regulatory network transitions. Trends Cell Biol. 21, 442-451.
182. Philippidou, D., Schmitt, M., Moser, D., Margue, C., Nazarov, P.V., Muller, A., Vallar, L., Nashan, D., Behrmann, I., and Kreis, S. (2010). Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 70, 4163-4173.
183. Pinner, S., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais, R., Bonvin, E., Goding, C., and Sahai, E. (2009). Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 69, 7969-7977.
184. Pleasance, E.D., Cheetham, R.K., Stephens, P.J. et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
185. Polyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273.
186. Prasmickaite, L., Skrbo, N., Hoifodt, H.K., Suo, Z., Engebraten, O., Gullestad, H.P., Aamdal, S., Fodstad, O.Y., and Malandsmo, G.M. (2010). Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell Melanoma Res. 23, 449-451.
187. Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., and Morrison, S.J. (2008). Efficient tumour formation by single human melanoma cells. Nature 456, 593-598.
188. Quintana, E., Shackleton, M., Foster, H.R., Fullen, D.R., Sabel, M.S., Johnson, T.M., and Morrison, S.J. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510-523.
189. Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., and De Maria, R. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115.
190. Richards, H.W., and Medrano, E.E. (2009). Epigenetic marks in melanoma. Pigment Cell Melanoma Res. 22, 14-29.
191. Roesch, A., Fukunaga-Kalabis, M., Schmidt, E.C., Zabierowski, S.E., Brafford, P.A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., and Herlyn, M. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594.
192. Roschke, A.V., Tonon, G., Gehlhaus, K.S., Mctyre, N., Bussey, K.J., Lababidi, S., Scudiero, D.A., Weinstein, J.N., and Kirsch, I.R. (2003). Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 63, 8634-8647.
193. Rukov, J.L., and Shomron, N. (2011). MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol. Med. 17, 412-423.
194. Salti, G.I., Manougian, T., Farolan, M., Shilkaitis, A., Majumdar, D., and Das Gupta, T.K. (2000). Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 60, 5012-5016.
195. Sand, M., Gambichler, T., Sand, D., Altmeyer, P., Stuecker, M., and Bechara, F.G. (2011). Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi. Eur. J. Dermatol. 21, 18-21.
196. Santisteban, M., Reiman, J.M., Asiedu, M.K. et al. (2009). Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 69, 2887-2895.
197. Satzger, I., Mattern, A., Kuettler, U., Weinspach, D., Voelker, B., Kapp, A., and Gutzmer, R. (2010). MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 126, 2553-2562.
198. Schäfer, J., and Strimmer, K. (2005). An empirical Bayes approach to inferring large-scale gene association networks. Bioinformatics 21, 754-764.
199. Schatton, T., Murphy, G.F., Frank, N.Y. et al. (2008). Identification of cells initiating human melanomas. Nature 451, 345-349.
200. Scheel, C., and Weinberg, R.A. (2011). Phenotypic plasticity and epithelial-mesenchymal transitions in cancer - and normal stem cells? Int. J. Cancer 129, 2310-2314.
201. Schickel, R., Boyerinas, B., Park, S.M., and Peter, M.E. (2008). MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27, 5959-5974.
202. Schlegel, N.C., Eichhoff, O.M., Hemmi, S., Werner, S., Dummer, R., and Hoek, K.S. (2009). Id2 suppression of p15 counters TGF-β-mediated growth inhibition of melanoma cells. Pigment Cell Melanoma Res. 22, 445-453.
203. Schultz, J., Lorenz, P., Gross, G., Ibrahim, S., and Kunz, M. (2008). MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 18, 549-557.
204. Segal, E., Shapira, M., Regev, A., Pe'er, D., Botstein, D., Koller, D., and Friedman, N. (2003). Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat. Genet. 34, 166-176.
205. Segura, M.F., Hanniford, D., Menendez, S. et al. (2009). Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. USA 106, 1814-1819.
206. Segura, M.F., Belitskaya-Lévy, I., Rose, A.E. et al. (2010). Melanoma microRNA signature predicts post-recurrence survival. Clin. Cancer Res. 16, 1577-1586.
207. Selzer, E., Wacheck, V., Lucas, T. et al. (2002). The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res. 62, 2098-2103.
208. Sensi, M., Catani, M., Castellano, G. et al. (2011). Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J. Invest. Dermatol. doi:.
209. Shackleton, M. (2010). Normal stem cells and cancer stem cells: similar and different. Semin. Cancer Biol. 20, 85-92.
210. Shackleton, M., and Quintana, E. (2010). Progress in understanding melanoma propagation. Mol. Oncol. 4, 451-457.
211. Shackleton, M., Quintana, E., Fearon, E.R., and Morrison, S.J. (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829.
212. Shah, A.A., Leidinger, P., Blin, N., and Meese, E. (2010a). miRNA: small molecules as potential novel biomarkers in cancer. Curr. Med. Chem. 17, 4427-4432.
213. Shah, M., Bhoumik, A., Goel, V. et al. (2010b). A role for ATF2 in regulating MITF and melanoma development. PLoS Genet. 6, e1001258.
214. Sharma, S.V., Lee, D.Y., Li, B. et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80.
215. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401.
216. Smalley, K.S.M. (2009). Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol. 130, 28-37.
217. Smith, S.D., Kelley, P.M., Kenyon, J.B., and Hoover, D. (2000). Tietz syndrome (hypopigmentation/deafness) caused by mutation ofMITF. J. Med. Genet. 37, 446-448.
218. Sood, P., Krek, A., Zavolan, M., Macino, G., and Rajewsky, N. (2006). Cell-type-specific signatures of microRNAs on target mRNA expression. Proc. Natl. Acad. Sci. USA 103, 2746-2751.
219. Stark, M.S., Tyagi, S., Nancarrow, D.J., Boyle, G.M., Cook, A.L., Whiteman, D.C., Parsons, P.G., Schmidt, C., Sturm, R.A., and Hayward, N.K. (2010). Characterization of the melanoma miRNAome by deep sequencing. PLoS ONE 5, e9685.
220. Steingrímsson, E., Copeland, N.G., and Jenkins, N.A. (2004). Melanocytes and the microphthalmia transcription factor network. Annu. Rev. Genet. 38, 365-411.
221. Strauss, D.C., and Thomas, J.M. (2010). Transmission of donor melanoma by organ transplantation. Lancet Oncol 11, 790-796.
222. Strub, T., Giuliano, S., Ye, T., Bonet, C., Keime, C., Kobi, D., Le Gras, S., Cormont, M., and Davidson, I. (2011). Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 30, 2319-2332.
223. Tachibana, M., Takeda, K., Nobukuni, Y., and Urabe, K. (1996). Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. Nat. Genet. 14, 50-54.
224. Takeshita, F., Patrawala, L., Osaki, M. et al. (2009). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18, 181-187.
225. Tapscott, S.J. (2005). The circuitry of a master switch: Myod and the regulation of skeletal muscle gene transcription. Development 132, 2685-2695.
226. Tassabehji, M., Newton, V.E., and Read, A.P. (1994). Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat. Genet. 8, 251-255.
227. Thomas, I., Kihiczak, G.G., Fox, M.D., Janniger, C.K., and Schwartz, R.A. (2004). Piebaldism: an update. Int. J. Dermatol. 43, 716-719.
228. Thomson, J.M., Newman, M., Parker, J.S., Morin-Kensicki, E.M., Wright, T., and Hammond, S.M. (2006). Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 20, 2202-2207.
229. Thurber, A.E., Douglas, G., Sturm, E.C., Zabierowski, S.E., Smit, D.J., Ramakrishnan, S.N., Hacker, E., Leonard, J.H., Herlyn, M., and Sturm, R.A. (2011). Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30, 3036-3048.
230. Tong, A.W., and Nemunaitis, J. (2008). Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther. 15, 341-355.
231. Trang, P., Medina, P.P., Wiggins, J.F. et al. (2010). Regression of murine lung tumors by the let-7 microRNA. Oncogene 29, 1580-1587.
232. Tseng, W., Fadaki, N., and Leong, S. (2011). Metastatic tumor dormancy in cutaneous melanoma: does surgery induce escape? Cancers 3, 730-746.
233. Tsuda, M., Davis, I.J., Argani, P., Shukla, N., McGill, G.G., Nagai, M., Saito, T., Laé, M., Fisher, D.E., and Ladanyi, M. (2007). TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 67, 919-929.
234. Van Gele, M., Dynoodt, P., and Lambert, J. (2009). Griscelli syndrome: a model system to study vesicular trafficking. Pigment Cell Melanoma Res. 22, 268-282.
235. Visone, R., and Croce, C.M. (2009). MiRNAs and cancer. Am. J. Pathol. 174, 1131-1138.
236. Volinia, S., Calin, G.A., Liu, C.-G. et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103, 2257-2261.
237. Waddington, C.H. (1942). Canalization of development and the inheritance of acquired characters. Nature 150, 563-565.
238. Wajapeyee, N., Serra, R. W., Zhu, X., Mahalingam, M., and Green, M. R. (2008). Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363-374.
239. Wang, J.C.Y., and Dick, J.E. (2005). Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494-501.
240. Wang, E.A.U., Voiculescu, S., Le Poole, I.C., El-Gamil, M., Li, X., Sabatino, M., Robbins, P.F., Nickoloff, B.J., and Marincola, F.M. (2006). Clonal persistence and evolution during a decade of recurrent melanoma. J. Invest. Dermatol. 126, 1372-1377.
241. Wang, J., Sakariassen, P.Ø., Tsinkalovsky, O. et al. (2008). CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 122, 761-768.
242. Weinberg, R.A. (1998). One Renegade Cell: How Cancer Begins. (New York, NY: Basic Books).
243. Weinstein, I.B., and Joe, A. (2008). Oncogene addiction. Cancer Res. 68, 3077-3080.
244. Wellbrock, C., and Marais, R. (2005). Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 170, 703-708.
245. Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., and Marais, R. (2008). Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3, e2734.
246. Weterman, M.J., Van Groningen, J.J., Jansen, A., and Van Kessel, A.G. (2000). Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. Oncogene 19, 69-74.
247. White, N.M.A., Fatoohi, E., Metias, M., Jung, K., Stephan, C., and Yousef, G.M. (2011). Metastamirs: a stepping stone towards improved cancer management. Nat. Rev. Clin. Oncol. 8, 75-84.
248. Widlund, H.R., and Fisher, D.E. (2003). Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22, 3035-3041.
249. Wiltshire, R.N., Duray, P., Bittner, M.L., Visakorpi, T., Meltzer, P.S., Tuthill, R.J., Liotta, L.A., and Trent, J.M. (1995). Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res. 55, 3954-3957.
250. Winnepenninckx, V., Lazar, V., Michiels, S. et al. (2006). Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst. 98, 472-482.
251. Worley, L.A., Long, M.D., Onken, M.D., and Harbour, J.W. (2008). Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 18, 184-190.
252. Yanaihara, N., Caplen, N., Bowman, E. et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198.
253. Yasumoto, K.-I., Mahalingam, H., Suzuki, H., Yoshizawa, M., Yokoyama, K., and Shibahara, S. (1995). Transcriptional activation of the melanocyte-specific genes by the human homolog of the mouse microphthalmia protein. J. Biochem. 118, 874-881.
254. Yoo, A.S., Sun, A.X., Li, L., Shcheglovitov, A., Portmann, T., Li, Y., Lee-Messer, C., Dolmetsch, R.E., Tsien, R.W., and Crabtree, G.R. (2011). MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476, 228-231.
255. Zhang, L., Huang, J., Yang, N. et al. (2006). microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA 103, 9136-9141.
256. Zhong, Y., Guan, K., Zhou, C., Ma, W., Wang, D., Zhang, Y., and Zhang, S. (2010). Cancer stem cells sustaining the growth of mouse melanoma are not rare. Cancer Lett. 292, 17-23.
257. Zhu, S., Wurdak, H., Wang, Y. et al. (2009). A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc. Natl. Acad. Sci. USA 106, 17025-17030.
258. Zhuang, L., Lee, C.S., Scolyer, R.A., Mccarthy, S.W., Zhang, X.D., Thompson, J.F., and Hersey, P. (2006). Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol. 20, 416-426.